When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
PRTO - Proteon's vonapanitase flunks second late-stage study
Proteon Therapeutics Inc.
A Phase 3 clinical trial, PATENCY-2, evaluating Proteon Therapeutics' (NASDAQ:PRTO) vonapanitase in chronic kidney disease (CKD) patients undergoing the creation of a radiocephalic fistula (vascular access in the wrist area) for hemodialysis failed to beat placebo.
More news on: Proteon Therapeutics, Inc., Healthcare stocks news, Stocks on the move,